Lexicon Pharmaceuticals, Inc. LXRX Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Aug 05, 2022 (filed on Aug 09, 2022)

Insider Name:

Invus US Partners LLC

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

147,390

Price:

$2.50
Aug 05, 2022 (filed on Aug 09, 2022)

Insider Name:

Artal International S.C.A.

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

2,426,070

Price:

$2.50
Aug 01, 2022 (filed on Aug 01, 2022)

Insider Name:

Debbane Raymond

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

982,600

Price:

$2.50
Aug 01, 2022 (filed on Aug 01, 2022)

Insider Name:

Invus US Partners LLC

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

982,600

Price:

$2.50
Aug 01, 2022 (filed on Aug 01, 2022)

Insider Name:

Artal International S.C.A.

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

16,173,800

Price:

$2.50
May 21, 2022 (filed on May 23, 2022)

Insider Name:

Swain Judith L

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Units

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

9,302

Price:

--
May 21, 2022 (filed on May 23, 2022)

Insider Name:

Swain Judith L

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

14,402

Price:

--
May 21, 2022 (filed on May 23, 2022)

Insider Name:

Sobecki Christopher J

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Units

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

9,302

Price:

--
May 21, 2022 (filed on May 23, 2022)

Insider Name:

Sobecki Christopher J

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

14,402

Price:

--
May 21, 2022 (filed on May 23, 2022)

Insider Name:

Nies Alan S

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Units

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

9,302

Price:

--

Filings by filing date

Aug 05, 2022 (filed on Aug 09, 2022)

Insider Name:

Invus US Partners LLC

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

147,390

Price:

$2.50
Aug 05, 2022 (filed on Aug 09, 2022)

Insider Name:

Artal International S.C.A.

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

2,426,070

Price:

$2.50
Aug 01, 2022 (filed on Aug 01, 2022)

Insider Name:

Debbane Raymond

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

982,600

Price:

$2.50
Aug 01, 2022 (filed on Aug 01, 2022)

Insider Name:

Invus US Partners LLC

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

982,600

Price:

$2.50
Aug 01, 2022 (filed on Aug 01, 2022)

Insider Name:

Artal International S.C.A.

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

16,173,800

Price:

$2.50
May 21, 2022 (filed on May 23, 2022)

Insider Name:

Swain Judith L

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Units

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

9,302

Price:

--
May 21, 2022 (filed on May 23, 2022)

Insider Name:

Swain Judith L

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

14,402

Price:

--
May 21, 2022 (filed on May 23, 2022)

Insider Name:

Sobecki Christopher J

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Units

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

9,302

Price:

--
May 21, 2022 (filed on May 23, 2022)

Insider Name:

Sobecki Christopher J

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

14,402

Price:

--
May 21, 2022 (filed on May 23, 2022)

Insider Name:

Nies Alan S

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Units

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

9,302

Price:

--

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	8800 TECHNOLOGY FOREST PLACE 8800 TECHNOLOGY FOREST PLACE THE WOODLANDS TX 77381
Tel:	N/A
Website:	https://www.lexpharma.com
IR:	See website

Key People

Jeffrey L. Wade President, Chief Financial Officer	Lonnel Coats Chief Executive Officer, Director	Alan J. Main Executive Vice President - Innovation and Chemical Sciences
Brian T. Crum Senior Vice President, General Counsel	Craig B. Granowitz Senior Vice President, Chief Medical Officer	Kenneth B. Kassler-Taub Senior Vice President - Regulatory and Quality Assurance
Kristen L. Alexander Vice President - Finance and Accounting	Wendy E. Mcdermott Vice President - Human Resources	Kiernan A. Seth Vice President, Chief Commercial Officer

Business Overview

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its pipeline includes Sotagliflozin, LX9211, and LX2761. Sotagliflozin is an orally-delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes, heart failure and chronic kidney disease. LX9211 is an orally-delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. LX2761 is an orally-delivered small molecule compound that is designed to inhibit sodium-glucose cotransporter 1 (SGLT1) locally in the gastrointestinal tract without any inhibition of sodium-glucose cotransporter 2 (SGLT2) in the kidney.

Financial Overview

For the six months ended 30 June 2022, Lexicon Pharmaceuticals, Inc. revenues decreased 72% to $72K. Net loss increased 23% to $48.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development -other increase of 28% to $26.2M (expense), General and administrative - other increase of 21% to $15.7M (expense).

Employees:	87 as of Feb 28, 2022

Reporting Currency:	U.S. Dollars
Enterprise value:	$444.60M as of Jun 30, 2022
Annual revenue (TTM):	$0.11M as of Jun 30, 2022
EBITDA (TTM):	-$95.25M as of Jun 30, 2022
Net annual income (TTM):	-$96.80M as of Jun 30, 2022
Free cash flow (TTM):	-$88.13M as of Jun 30, 2022
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	183,625,743 as of Aug 3, 2022
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization